KNW (Know Labs) Capex-to-Revenue : 0.00 (As of Sep. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Know Labs Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Know Labs's Capital Expenditure for the three months ended in Sep. 2024 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Know Labs Capex-to-Revenue Historical Data

The historical data trend for Know Labs's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Know Labs Capex-to-Revenue Chart

Know Labs Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Capex-to-Revenue

Get a 7-Day Free Trial

0.57

0.20

Know Labs Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Capex-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Know Labs's Capex-to-Revenue

For the Scientific & Technical Instruments subindustry, Know Labs's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Know Labs's Capex-to-Revenue Distribution in the Hardware Industry

For the Hardware industry and Technology sector, Know Labs's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Know Labs's Capex-to-Revenue falls into.

Know Labs Capex-to-Revenue Calculation

Know Labs's Capex-to-Revenue for the fiscal year that ended in Sep. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.066)	/	0
	=	N/A

Know Labs's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Know Labs (AMEX:KNW) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Know Labs Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Know Labs's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Know Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Hardware » Know Labs Inc (AMEX:KNW) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Union Street, Suite 810, Seattle, WA, USA, 98101

Website

https://www.knowlabs.co

Know Labs Inc is a medical diagnostic. The company is focused on the development, marketing, and sales of proprietary technologies that are capable of uniquely identifying or authenticating almost any substance or material using electromagnetic energy to record, detect, and identify the signature of the substance or material known as Bio-RFID and ChromaID technologies. It is developing a wearable device that will measure blood glucose without fingersticks or microneedles.

Executives

Todd Baszucki	10 percent owner	519 LOMA ALTA ROAD, CARMEL CA 93923
Jessica English	officer: Chief Marketing Officer	34 GRANADA DRIVE, CORTE MADERA CA 94925
Leonardo Mouta Trautwein	officer: Chief Marketing Officer	PO BOX 2021, PARK CITY UT 84060
Takesako Ichiro John Paul	director	500 UNION STREET, SUITE 420, SEATTLE WA 98101
Peter J Conley	officer: Chief Financial Officer	3658 PRICE HILLS DRIVE, SAINT GEORGE UT 84790
Steven T Kent	officer: Chief Product Officer	185 CHANNEL ST, APT 545, SAN FRANCISCO CA 94158
William Arthur Owens	director	C/O CENTURYLINK, INC., 100 CENTURYLINK DRIVE, MONROE LA 71203
Ronald P Erickson	director, officer: Chairman	9437 NE CORAL COURT, BAINBRIDGE ISLAND WA 98110
Jon Pepper	director	500 UNION STREET, SUITE 810, SEATTLE WA 98101
Phillip Bosua	director, 10 percent owner, officer: CEO and President	500 UNION STREET, SUITE 810, SEATTLE WA 98101
Jeff T Wilson	officer: CFO
Jeffrey Richard Kruse	other: Pres. of TransTech Systems Inc	12142 NE SKY LANE, SUITE 130, AURORA OR 97002
Todd Martin Sames	officer: V.P. of Business Development	500 UNION STREET, SUITE 420, SEATTLE WA 98101
Richard Mander	officer: VP Product Mgmnt & Technology	500 UNION STREET, STE 406, SEATTLE WA 98101
Bonderson Paul R Jr	director